Pfizer’s “different batches”

https://thehotstar.net/separatebatches.html

We have long assumed the “good for me but not for thee” stance on covid vaccines.  We have discussed many times fake vax cards, elites being registered as vaccinated but never had a covid vaccine, and the fact that congress, the white house, USPS, NIADH never had a covid vaccine mandate or requirement.  I would bet a weeks wages that any politician getting a vaccine on TV was getting something different than the general population got.  Thank you to a fantastic amazing follower who I also call my friend for sending me this link.  Today I share it with all of you.

Data demonstrate the presence of significant amounts of truncated/modified forms of mRNA at somewhat higher levels in the batches manufactured with the commercial process as compared to material used in clinical trials. These forms are poorly characterised, and the limited data provided for protein expression do not fully address the uncertainties relating to the risk of translating proteins/peptides other than the intended spike protein.

– Comirnaty(Pfizer BioNTech) COVID-19 mRNA vaccine Assessment Report, page 35

In an interview, BioNTech CEO Ugur Sahin states neither himself nor his employees had yet been vaccinated, but they planned to “make an extra batch independent from the European contingent” available to themselves and corporate partners. The direct quote can be found in the below video.

The employee specific program he proposed was then instituted in January with further details of it announced in a company press release:

The additional small quantities of vaccine used for this purpose are separate and distinct from those committed under the supply agreements entered in to with the European Commission and other governments, and will not impact BioNTech’s ability to meet its commitments under these supply agreements.

– Statement on Voluntary COVID-19 Vaccination for BioNTech Employees and Suppliers to Ensure Undisrupted Manufacturing and Distribution of COVID-19 Vaccine Doses, archive link

So the BioNTech employee and associate mRNA gene therapy vaccine solution was produced in small quantity batches "separate and distinct" from those "committed under the supply agreements" as to not "impact BioNTech’s ability to meet its commitments under these supply agreements". In other words, BioNTech did not use the commercial batch manufacturing process for itself and instead used the clinical batch manufacturing process. And it did this ostensibly to meet its commercial supply commitments.

Data analysis using the VAERS database, the authoritative system used in the United States to report vaccine induced adverse events and deaths through post-market surveillance, would appear to show an uneven distribution of both reported deaths and AE across vaccine batch numbers for both the Moderna and Pfizer mRNA gene therapy vaccines. I have not verified the following analysis, but they are done using publicly available data.

100% of Covid-19 Vaccine Deaths were caused by just 5% of the batches produced according to official Government data, archive link

100% of Covid-19 Vaccine Permanent Disabilities and Deaths among Children were caused by just 6% of the batches produced according to official Government data, archive link

According to their website, Pfizer Australia has 1,700 employees. Even accounting for family and corporate partners, it remains a little odd that 15% of all Pfizer batches registered in Australia would be allocated for use in the Pfizer Employee Program. Though it turns out they were, only some of the time.

These eight batches, unlike the other 54 commercial batches, are not tested by the TGA as are all commercial batches, as they instead recognise the testing certification done by the European Union's Official Control Authority Batch Release(OCABR).

Pathway one uses overseas certification as evidence that the batch has already undergone independent testing and assessment by a recognised National Control Laboratory, such as the  in Europe.
The OCABR process involves assessment of manufacturing documentation (summary protocol review) and laboratory testing for potency, identity and appearance based on guidelines for specific COVID-19 vaccine types (e.g. RNA, viral vector, and inactivated vaccines).
When the Sponsor provides evidence that the batch supplied in Australia has passed OCABR testing, the vaccine can be released without the TGA conducting a manufacturing protocol assessment or (potentially) laboratory testing.
The Sponsor must still supply samples, batch details and evidence of the maintenance of adequate shipping conditions for the batch under this pathway.
OCABR certificates are unlikely to be available for all COVID-19 vaccine batches as their availability depends on many factors, including the final global distribution of a batch.

– TGA - Batch release assessment of COVID-19 vaccines

The status of these eight batches, as reflected in the TGA batch registry system, have undergone some irregularities throughout the course of 2021. The discovery of these irregularities were made by someone conducting an independent audit of vaccine supply to the Australian government. This audit can be found here, though it isn't pertinent to the issue at hand:

Covid Supply Background Notes Covid-19 Supply Audit

As of August 10th 2021, the TGA batch registry had five batches allocated to the Pfizer employee vaccination program.  You can see them below.

The evolution of entries of batch FA4598 alone is as follows:

Up until August 11th:
Batch FA4598 - 22 June 2021, Marked for Pfizer Employees.

From August 11th-19th:
Batch FA4598 - 22 June 2021, Marked for Pfizer Employees.
Batch FA4598 - 30 June 2021, Untested additional shipment.

From August 19th - September 21st:
Batch FA4598 - 30 June 2021, Untested additional shipment.

From September 19th - December 9th 2021:
Batch FA4598 - 30 June 2021, Marked for Pfizer Employees.

Based on the totality of evidence, it is reasonable to believe that specific batches of the mRNA gene therapy vaccine solution produced using commercial batch process 2 may lead to substantially higher reports of adverse events and death than batches of the mRNA gene therapy vaccine substance produced using clinical batch process 1. If this is reasonable to believe, then it would reasonably follow those aware of the increased risk of commercial batches, would seek to reduce this risk through administering a mRNA gene therapy vaccine solution from a clinical batch to themselves and families.